Our focus is on unlocking the full therapeutic potential of the NO-cGMP pathway to address a broad range of serious CNS diseases.
We have the expertise, team and determination to bring innovative medicines forward for patients.
Our pipeline is focused on programs for serious CNS diseases.
CY6463 is the revised compound name for IW-6463. IW-6463 will be referenced in various existing articles, trial descriptions, etc.
Leaders in Drug Discovery and Development
We are world leaders in targeting the nitric oxide-cGMP pathway in the CNS.
Our team has an exceptional track record bringing meaningful therapies to patients.